[Innovation or pseudo-innovation: that is the question].
作者信息
Unger Thomas
机构信息
Center for Cardiovascular Research (CCR)/Institut für Pharmakologie und Toxikologie, Charité-Universitätsmedizin, Berlin.
出版信息
Med Klin (Munich). 2006 Mar 15;101(3):257-62. doi: 10.1007/s00063-006-1034-8.
PMID:16648986
Abstract
摘要
相似文献
1
[Innovation or pseudo-innovation: that is the question].
Med Klin (Munich). 2006 Mar 15;101(3):257-62. doi: 10.1007/s00063-006-1034-8.
2
[Real and assumed potential savings in antihypertensive treatment. Right out of the magician's hat].
Dtsch Med Wochenschr. 2003 Jul 11;128(28-29):1557-9. doi: 10.1055/s-2003-40387.
3
[Hypertension therapy--never without diuretics?].
MMW Fortschr Med. 2007 Nov 15;149(46):31-3.
4
[Economic or medical innovations: that is the question!].
Med Klin (Munich). 2006 Jul 15;101(7):590-1; author reply 591-3.
5
[Comment on IOWiG report plan. A medical decision may not be replaced].
MMW Fortschr Med. 2006 May 11;148(19):42.
6
[Therapy of hypertension. Cost conscious prevention of complications].
MMW Fortschr Med. 2003 Nov 20;145(47):64.
7
Hypertension control: improved, but not enough!
Am J Hypertens. 2007 Apr;20(4):347. doi: 10.1016/j.amjhyper.2007.02.002.
8
Antihypertensive pharmacotherapy in a developing economy: pattern, acquisition costs and conformity to international guidelines in a tertiary-care setting.
J Hum Hypertens. 2006 Nov;20(11):894-7. doi: 10.1038/sj.jhh.1002080. Epub 2006 Aug 10.
9
[Fully possible to reduce the costs of hypertension treatment].
Lakartidningen. 2009;106(23):1558-62.
10
[Treating hypertension only in case of high risk? Evidence-based therapy with cost control].
MMW Fortschr Med. 2001 Feb 15;143(7):45-6.
Zotero 插件